Among all the inaccurate things that are stated about

New Post Public Reply Private Reply Replies (0) Message Board
bejamin
Among all the inaccurate things that are stated about Cellceutix the top 2 seem to be time line and credibility. Both can be squashed with good DD. As the company moves forward, especially in such a position of success, there will be many that try to mince every word that is written and or said.

Facts -
The company never gave any time line to up-list except one time in an interview saying the plan was for this year (2015) The rumblings that this has lead investors wrong is very inaccurate! As good as Cellceutix has been at keeping investors updated(I for one have appreciated), has also keep the wolves close by the door. Giving them the opportunity to smash down every bit of news that is released and turn it in to a non event, as seen in the false SA article. So they will keep carrying that torch and may proclaim that partner or up-list is the only way to save the company.The company doesn't require a high SP to conduct and continue through trials this has been discussed ad nausseam! They only thing the attacks on the company have done was drop SP it hasn't slowed anything else down! Well maybe partner discussions, but I don't even think that matters as Cellceutix stands in a position to negotiate anyway.

I would also like to state that Cellceutix has been working very hard to do the up-list so they are reporting and filing at the level required to be on NASDAQ, they aren't trying to con anybody.

When your doing your DD find it in print. You will be told things like Phase 2 is meaningless phase 3 is the answer, the same thing was said about phase 1 to phase 2. Phase 3 is a given now and just waiting for the "real" time it takes to set up a trial. But if you look at the phase 2 results you will see phase 3 has been very de-risked by the quality of the results. Kevetrin is the same thing phase one took longer than expected(welcome the world of medicine development). But the quality of the results are outstanding, by a hospital that is equally outstanding!
Cellceutix isn't a guaranteed success by no means. But if you take a look at where it is, I would much rather be putting my money in a bio with 5 trials, 3 major drugs and phase 2s going on and completed and a phase 3 about to start, over a bio with one drug. Do the math look around compare values of companies.
When you get to money "issue" they have a lot of funding on hand, should they need it. Take a good look at how much the company is burning through! They are using a lot of grants and some trials they are just supplying the drugs.

Remember it is the internet where names have been change to protect... everybody... so consider the source of the information you receive. Then make a real assessment of the company if you are really considering investing in the company on the long side!


Know What you own

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Keep in mind that message boards require you to agree to thier manipulation or you are a lying basher! Also remember those that accuse are often riddle with quilt of performing the same which they accuse.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Smart Salary Moves for S Corp Owners: Riggs Unpacks Insights

Updated Category News Views 192

Decoding the S Corp Salary Dance How much salary should the savvy owners of S corporations draw? It ain't a simple task or one-size-fits-all deal, folks. David Riggs spills the beans on HelloNation, sharing insights on this complex tango between drawing wages and raking in shareholder distributions. In the end, it’s about playing by the IRS rules—or risking a penalty...

Continue Reading
OlloBot's Emotional AI Robots Connect Beyond Tasks

Updated Category News Views 358

OlloBot Eyes Emotional Bonds, Not Just Robotics Power Is it just me, or is OlloBot onto something deep with their emotional AI companions? They've set a course that might just redefine how we perceive home robotics. At IFA Berlin 2026, they didn't just strut their technical stuff. Nope, they took it beyond gears and gadgets, turning heads with a robot that does more than...

Continue Reading
Abbott's SonicForce Impresses in Crucial Clinical Trial

Updated Category News Views 0

Breaking Through Cardiac Barriers Never thought I'd see the day when we're literally sending shockwaves through the heart, but here we are. Abbott's makin' waves, quite literally, with its SonicForce™ Coronary Intravascular Lithotripsy (IVL) System. They’ve just dropped some promising 30-day outcomes from the TECTONIC study, which has grabbed the spotlight at the...

Continue Reading
Navigating Underinsured Motorist Coverage Woes

Updated Category News Views 109

When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...

Continue Reading
Dutch Bros Pours Holiday Cheer with New Festive Menu

Updated Category News Views 145

New Festive Offerings from Dutch Bros Kicking off the holiday season with a splash of vibrant flavors, Dutch Bros is shaking up the menu with some fresh, festive entries. Two new drink concoctions hit the stage alongside a themed delectable treat, and for those traditionalists, perennial favorites make a triumphant return. Dutch Bros Expands Its Vibrant Lineup It's not...

Continue Reading
Termite Swarmers: Essential Clues and Action Steps

Updated Category News Views 144

Understanding the Intrusive Nature of Termite Swarmers When it comes to creepy crawlies wreaking havoc on your beloved abode, termites are the stealthy troublemakers you need to keep an eye out for. Just because you catch a glimpse of them doesn't mean the damage is obvious or minimal. Spotting the Culprits: Termites vs. Ants Identifying what you're up against is the...

Continue Reading
Brigham Nurses Dig In for Strike: Fight for Fairness

Updated Category News Views 49

Strike Looms as Brigham Nurses Demand Fair Treatment Massachusetts is gearing up for its largest open-ended nursing strike in history as Brigham and Women's Hospital nurses prepare to lay down their tools in pursuit of a just contract. This ain't your typical workplace squabble; it's a full-blown battle for patient safety and professional respect. The Core Grievances at...

Continue Reading
Perion Acquisition: Affle's Bold Leap in Ad Tech

Updated Category News Views 57

Affle's Strategic Acquisition of Perion Jumpin' through another hoop, Affle is gearing up to snag Perion in a hefty deal valued at about $420 million. For those of you not knee-deep in the ad tech sandbox, Affle—trading on the NSE as AFFLE—is aiming to ramp up its AI-driven conversion game by absorbing Perion, a veteran in the omnichannel advertising realm. "This...

Continue Reading
Aiper’s Black Friday Pool Deals Make a Splash

Updated Category News Views 120

Black Friday: A Pool Owner's Break It’s not every day you stumble upon savings like these—Aiper is throwing some meaty discounts this Black Friday, saving pool owners up to a juicy $550 off robotic cleaners. Imagine that! For anyone with a pool to maintain, these deals might just be the ticket to less grunt work and more time lounging with a cold drink in hand....

Continue Reading
SICO Snags $1.6B in New Investor Mandates for 2026

Updated Category News Views 68

SICO Makes Waves with Massive New Business Wins Right out of the gate at the Gateway Gulf 2026 Forum, SICO's announcement of a whopping $1.6 billion in new business mandates had even the seasoned pros raising an eyebrow or two. There's nothing like a sweet billion-dollar figure to kickstart the day, huh? This isn't small change we're talking about; this is a tidal wave of...

Continue Reading

Top 5 Most Recently Viewed Articles

111, Inc. Reports Strategic Q1 2026 Financial Shift

Updated Category News Views 32

Reinventing the Wheel: 111, Inc.'s Financial Upheaval Savvy investors, take note: 111, Inc. (NASDAQ:YI) just lobbed a financial curveball, waving their first quarter 2026 results like a bullfighter's cape. The spectacle? Revenues sliding downhill by over 33% to RMB2.4 billion (US$342.4 million). You might be tempted to scribble this off as a snooze, but the company's...

Continue Reading
Revolutionizing Commerce: Seamless Checkout within Chat Platforms

Updated Category News Views 225

Transforming the Shopping Experience with Innovative Commerce As social commerce trends continue to evolve, we anticipate a market that could very well reach an astonishing $2 trillion soon. In this landscape, Mind Over Media and Skipify have joined forces to create a groundbreaking Checkout-in-Chat service. This initiative allows customers to explore, make decisions, and...

Continue Reading
Long-Term US-Israel Security Pact Proposed for Future Stability

Updated Category News Views 169

Israel Proposes a New Security Agreement with the United States Israel is actively pursuing a substantial 20-year security agreement with the United States. This initiative includes provisions reflecting an 'America First' approach to enhance collaboration and support from the current U.S. administration. The goal is to solidify a long-term partnership to navigate complex...

Continue Reading
Certara Sets Date for Third Quarter Financial Report Release

Updated Category News Views 132

Certara Announces Financial Results Meeting Certara, Inc. (NASDAQ: CERT), a global leader in biosimulation, is gearing up to share its third quarter financial performance for 2025. The announcement comes as part of the company's commitment to transparency and investor engagement. Conference Call Details Scheduled for Thursday, November 6, 2025, Certara plans to release...

Continue Reading
Swissmedic Grants Approval for New IgA Nephropathy Treatment

Updated Category News Views 154

Switzerland Approves Innovative Treatment for IgA Nephropathy In a significant advancement for kidney health, CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) have announced that the Swiss regulatory authority, Swissmedic, has granted temporary marketing authorization for FILSPARI (sparsentan). This approval marks a crucial step forward in the treatment of IgA...

Continue Reading